Infleqtion and Churchill Capital Corp X Complete $3.6B Merger
Churchill Capital Corp X and Infleqtion have completed their merger, creating a pro forma enterprise value of $3.6 billion and netting $525 million from the SPAC trust. Shares of the combined company will begin trading under the ticker INFX on the NYSE.
1. Transaction Highlights
The business combination between Infleqtion and Churchill Capital Corp X has closed, establishing a pro forma enterprise value of $3.6 billion and unlocking $525 million in trust proceeds. This capital infusion is earmarked to advance Infleqtion’s mRNA therapeutic development pipeline.
2. Trading Debut
Following the merger, the combined entity’s ordinary shares will begin trading on the New York Stock Exchange under the ticker INFX, providing public market investors direct exposure to Infleqtion’s technology platform and drug candidates.